Noida (Uttar Pradesh) [India], November 11 (ANI/PRNewswire): Curadev Pharma is pleased to announce their collaboration with Dr. Winsley Rose and other clinicians at CMC, Vellore, to study biomarkers of immune suppression in dengue patients.

Increased activation of the kynurenine pathway has been postulated as a mechanism by which the dengue virus and a variety of infectious agents evade host immunity.

Also Read | Yemen’s Houthi Militia Claim Responsibility for Ballistic Missile Attack on Saudi Military Base.

As dengue is endemic to parts of India, this partnership aims to map plasma kynurenine and tryptophan levels as a function of disease severity.

From its inception, Curadev has sought and nurtured alliances with leading academicians and institutions to create a forum for dialog and translational research.

Also Read | Leonardo DiCaprio Birthday Special: 10 Hard-Hitting Quotes by the Titanic Actor That Are Motivating and Speaks About Success.

Curadev will provide the technical and financial resources required to support the clinical study carried out by CMC Vellore clinicians.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)